RT Journal Article SR Electronic T1 Pharmacogenomics in Lung Cancer Chemotherapy: A Review of What the Oncologist Should Know JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5241 OP 5250 VO 34 IS 10 A1 CHIARA D'ANTONIO A1 ANNALISA MILANO A1 RICCARDO RIGHINI A1 CONCETTA ELISA ONESTI A1 MARIA BASSANELLI A1 ROSA FALCONE A1 IDA PARIS A1 SALVATORE LAURO A1 PAOLO MARCHETTI YR 2014 UL http://ar.iiarjournals.org/content/34/10/5241.abstract AB Lung cancer is the leading cause of cancer-related death around the world; the addition of chemotherapy to treatment of this disease has been shown to significantly increase progression-free survival and overall survival. Despite newer chemotherapies, it is important to personalize the care (treatment and dose) upon each single patient's susceptibility for controlling and reducing adverse side-effects, at best. The present review describes the current status of pharmacogenomics studies regarding germline DNA variants that may alter response and tolerability to chemotherapeutic agents used to treat lung cancer, including perspective studies.